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Abstract
Introduction: Autoantibody-mediated autoimmunity directed against targets within the voltage-gated potassium channel complex
(VGKCC autoantibodies) has been implicated in causing neuropathic pain.
Methods: We report the case of a 76-year-old, United Kingdom male who was diagnosed with contactin-associated protein 2
(CASPR2) autoantibody–associated Morvan syndrome, a rare neurological condition.
Results: He had previously worked in a swine abattoir; exposure to aerosol within swine abattoirs has been reported to elicit an
immune response resulting in the production of these autoantibodies; however, unusually, his manifestations emerged with several
years’ latency. Although this patient’s Morvan syndrome–associated seizures were well-controlled with antiepileptic drugs, his
neuropathic pain and painful muscle fasciculations did not respond to pharmacological interventions. He refused painmanagement
program treatment, but high-dose immunoglobulin treatment or treatment with rituximab, reported to be sometimes effective in this
group, was not initiated because of concerns regarding his general frailty.
Discussion and Conclusion: This case highlights issues around the identification and treatment of rare patients with chronic pain
who have voltage-gated potassium channel complex autoantibodies; it also emphasizes the possibility that former swine abattoir
workers might be at risk of developing neuropathic pain even years after their vocational exposure.
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1. Introduction
A 76-year-old gentleman attended the outpatient clinic at our
Department of Pain Medicine in 2016 after referral by his
neurologist. He complained of severe pain with a toothache-like
character on the back of both legs, extending from the buttocks
to the knees; in addition, he had recent onset severe burning pain
affecting the outside of the left knee and the right groin.
Review of his medical notes revealed variability of his
complaints. In previous consultations, by other departments, he
had complained of “firing, cramping, spasmodic pain,” occurring
in intervals of several days and affecting medial–posterior thighs,
and feet below ankles.
His medical history is given in the supplementary appendix A
(available at http://links.lww.com/PR9/A28). He had first de-
veloped nonpainful, muscle-related problems 5 years before
presentation to us, with episodes of sudden involuntary twitching
of eyelid muscles (myokymia) and fasciculating facial muscle
movements. Initial electromyography showed myokymic dis-
charges in orbicularis oculi bilaterally, but not abnormalities in limb
muscles. Several months later, he had been observed to have
“vacant spells.” On assessment by a neurologist, routine blood
tests, computed tomography, and magnetic resonance imaging
of the brain did not show significant abnormality. An electroen-
cephalogram showed focal epileptiform discharges in the right
midtemporal area, with simultaneous bradycardia. He was
diagnosed as having complex partial seizures and started on
sodium valproate with good improvement of his vacant episodes.
Four months later (in 2012), he had started to notice prominent
cramps and twitches in his legs, ankles, and thighs, in addition to
a constant “tight uncomfortable feeling almost amounting to
pain”, and then shortly thereafter, he first reported pain in his back
and thighs. He did not complain about dysautonomia, and his
sleep was only intermittently disturbed.
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He was noted as thinly built. There was wasting of calf and
thigh muscles with muscle fasciculations. The rest of his
neuroexamination was normal, so that at this point, no clear
cause for his pain was found. He underwent further investiga-
tions. Repeat magnetic resonance imaging whole spine and
nerve conduction tests were normal. Electromyography showed
myokymic discharges in both orbicularis oculi, and scanty but
widespread fasciculation in multiple large leg muscles, in the
absence of denervation. Careful electromyography analysis on 2
occasions revealed no evidence for neuromyotonia or myokymic
discharges in limb muscles. Standard autoantibody tests and
antiglutamic acid decarboxylase or anti N-methyl-D-aspartate
receptor antibodies were negative. However, the serum voltage-
gated potassium channel complex (VGKCC) antibody titer was
elevated and remained raised on repeated testing. Detailed
testing with cell-based assays (John Radcliffe Hospital Oxford)
showed elevated CASPR2 (contactin-associated protein-like 2)
antibodies. CASPR2 antibody levels rose over 2 to 3 years from
250 to 700 pmol/L (positive .125) and then remained stable.
CASPR2 antibodies can be paraneoplastic,10 but additional
extensive investigations returned no abnormal results (supple-
mentary appendix B, available at http://links.lww.com/PR9/A28).
The most likely neurological diagnosis was deemed to be
VGKCC (CASPR2)-associated peripheral (peripheral nerve excit-
ability and pain, weight loss), and central (epilepsy) syndro-
me—Morvan syndrome,5 with no identified underlying trigger.
Because his seizures were well-controlled with valproate, the
reported most distressing symptoms were pains of mixed
character and muscle fasciculations/cramps.
The patient’s pain was diagnosed as neuropathic by his
neurologist in 2014. At that time, he was noted to recently have
received steroids for treatment of an exacerbation of his
concomitant chronic obstructive pulmonary disease (60-mg
prednisolone 3 3 days) and experienced moderate pain relief.
A pragmatic trial as an inpatient on 40-mg prednisolone daily
for several weeks, specifically to reduce his distressing and
painful symptoms was unsuccessful. He was tried on several
analgesic medications without benefit, including tramadol,
pregabalin to maximal dose, amitriptyline, and duloxetine.
Buprenorphine patches afforded moderate, short-lived pain
reduction, but he developed respiratory problems, with
consequent admission to A&E, and this had to be stopped.
Low-dose oxycontin/naloxone at 5 mg/2.5 mg was ineffective,
and dose increase caused inacceptable side effects, including
reduced cognition. There was short-lived pain reduction to
dihydrocodeine, whereas tapentadol at a low dose (50-mg BD)
was ineffective. Although his pain intensity a year before he
was seen by us was documented as only moderate, with 5/10
on an 11-point scale (05 no pain, 105 pain as bad as you can
imagine), the clinical impression by his treating team was of
a highly distressing problem.
During assessment at our Department of Pain Medicine in
2016, the patient revealed that he had worked as a swine
abattoir worker for many years up to the age of 60 years (7
years before his first presentation with abnormal muscle
symptoms). He had then worked as a butcher a further 5
years until age 65 when he retired.
Because VGKCC antibody–associated neuropathic pain has
been reported responsive to disease modification with immune-
modulating drugs,6 immune interventions were now further
discussed but were found unsuitable because of this patient’s
frailty and the lack of sufficient evidence. He was offered
attendance at a pain management program. He was first keen
to attend but later indicated that he was instead looking for a pain
cure. His mixed pains mainly affecting his legs were ongoing at
the end of 2017.
2. Discussion
We report an unusual case of delayed-onset intrusive chronic
neuropathic pain in a former swine abattoir worker diagnosed
with CASPR2 autoantibody–associated Morvan syndrome.
To our knowledge, this is the first published case of a swine
abattoir worker presenting with painful signs and symptoms
(1) outside the United States, (2) with a latency period of
several years after vocational exposure, (3) with Morvan
syndrome.
For practitioners in pain medicine, this case highlights the
emerging field of chronic pain associated with autoantibody-
mediated disorders4; it also emphasizes complexities around
potassium channel complex autoantibody–associated chronic
pains (Fig. 1). Antibodies to the VGKCC were initially identified by
radioimmunoassay based on dendrotoxin, which binds to
shaker-type voltage-gated potassium channel antibodies. Later
experiments showed, however, that the antibodies do not directly
bind to the potassium channels but to proteins with which they
complex, including CASPR2 and LGI1.5 Generally, although
potassium channels act as “brakes” for sensory neuron
excitability, the autoantibodies that bind to CASPR2 reduce
surface expression of potassium channels and consequently
cause hyperexcitability.2
(1) Potassium channel autoantibody complex (VGKCC)-
associated pain is typically reported as a feature in rare
neurological disorders caused by these antibodies, such as
neuromyotonia or myokymia (Morvan syndrome); these
disorders can sometimes be paraneoplastic.1,2,5
(2) A separate group of patients have neuropathic pain and
autoantibodies to CASPR 2, without having any neurological
abnormalities; encouraging results on pain relief after
treatmentwith immune therapies have been communicated.6
Figure 1. The VGKCC and associated proteins with LGI1- and CASPR2-
binding autoantibodies and associated neurological conditions. DTX, den-
drotoxin known to directly bind VGKCC; FBDS, faciobrachial dystonic
seizures; LE, limbic encephalitis; LGI1, leucine-rich glioma-inactivated 1;
MoS, Morvan syndrome; NMT, neuromyotonia; VGKCC, voltage-gated
potassium channel complex. Note some patients that are negative to both
LGI1 and CASPR2may have antibodies binding the intracellular domain of this
protein complex, but their pathophysiological role is uncertain. Recent
evidence suggests that painful neuropathic symptoms can arise in both
CASPR2-positive and LGI1-positive patients (from Irani SR, Vincent A.
Handbook of Clinical Neurology 2016,5 with permission).
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(3) A third group of patients with VGKCC-associated pain was
described in 2010/2012 by Mayo clinic neurologists. These
patients were swine abattoir workers, who developed acute or
subacute sensory-predominant polyradiculoneuropathy.7,9Work-
ers closest to the swine brain processing machinery were most
affected, and it was believed that patients had effectively been
immunizedby the inhalationof aerosolized swinebrainantigens, to
nowproduce autoantibodies directed against their own peripheral
nerves.Brainmanifestationswere rare, andnopatient hadMorvan
syndrome. Their painwas frequently aching andburning, involving
mostly legs (86%), arms, and the head/neck region. The
autoantibody serum titers in these patients reduced over time,
either spontaneously with the stop of exposure to swine brain
aerosol or with immune modulation treatment.
Our patient’s CASPR2-positive, painful neurological condition,
and his previouswork as swine abattoir workermay be coincidental.
However, given the rarity of each, we suggest this is unlikely, and it is
more likely that a past exposure to swine neural tissue aerosol
caused both his central neurological signs that were brought under
control, and the peripheral neuropathic pain for which we found no
effective treatment. We speculate that he might have had low-level
CASPR 2 antibodies for several years before symptoms started.
A limitation of our studywas that we did not examine the patient for
additional neuropathic pain diagnoses such as small fiber neuropathy.
There are diagnostic and therapeutic challenges concerning
CASPR2-associated chronic pain in general and abattoir-
working in specific:
(1) Although in this case the central and peripheral neurological
signs and symptomswere a “give away,” how canwe clinically
be alerted to the possibility that a particular patient’s peripheral
neuropathic painmay be caused by CASPR2 autoantibodies?
(2) Although there is some evidence for the efficacy of immune
treatments,3,6,8 given the lack of randomized controlled trials,
and the rarity of this condition, how shall we consider immune
therapy to reduce pain in either case, CASPR2 seropositivity
with/without neurological disorders?
(3) Should former swine abattoir workers be screened for
neuropathic pain and possibly as late as 5 to 10 years after
stop of their exposure?
In summary, we present a case of a patient with peripheral
neuropathic pain, CASPR2 serum autoantibodies, and Morvan
syndrome caused very likely by exposure to swine neural-tissue
aerosol several years ago. This case also highlights that
availability of internationally agreed guidance on diagnosis and
treatment of VGKCC autoantibody–associated neuropathic pain
would be useful to support clinical practice in pain medicine.
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